Sunshine Biopharma Inc. announced today that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Lurasidone, a new generic prescription drug. Lurasidone is a generic version of Latuda® and belongs to the therapeutic class of antipsychotics, used for schizophrenia. This launch targets the Canadian sector of the global $1.2 billion market for this drug.
The introduction of generic Lurasidone further diversifies Nora Pharma's product offerings and strengthens its presence in the Canadian pharmaceutical market. Expanding the portfolio with high-demand generic drugs is a key strategy for increasing market share and driving revenue growth. This contributes directly to the commercial segment's performance.
These generic drug launches are integral to Sunshine Biopharma's strategy of generating consistent commercial revenues. These revenues are crucial for funding the company's ongoing research and development efforts in its proprietary oncology and antiviral drug programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.